

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/909,715	07/20/2001	Brian J. Cox	18455.11	1492
31278	7590 02/24/20	EXAMINER		INER
	NG YOCCA CARLS	EREZO, DARWIN P		
SUITE 1600 660 NEWPORT CENTER DRIVE			ART UNIT	PAPER NUMBER
P.O. BOX 7		3731		
NEWPORT BEACH, CA 92660			DATE MAILED: 02/24/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

Υ						
	Application No.	Applicant(s)				
	09/909,715	COX, BRIAN J.				
Office Action Summary	Examiner	Art Unit				
	Darwin P. Erezo	3731				
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the	e correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING [- Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period. Failure to reply within the set or extended period for reply will, by statuly Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS from the course the application to become ABANDO	ON. timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 05 i	December 2005.					
2a) ☐ This action is FINAL. 2b) ☑ Th	This action is FINAL . 2b) ☑ This action is non-final.					
•						
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D. 11,	453 O.G. 213.				
Disposition of Claims						
4) ☐ Claim(s) 44-47,54-56,59-61 and 64-100 is/ard 4a) Of the above claim(s) 59,70-75,78-80 and 5) ☐ Claim(s) 69,81-85 and 95-100 is/are allowed. 6) ☐ Claim(s) 44-47,54-56,60,61,64-68,76,77 and 7) ☐ Claim(s) is/are objected to.	186 is/are withdrawn from consid	deration.				
8) Claim(s) are subject to restriction and/	or election requirement.					
Application Papers						
9) The specification is objected to by the Examination The drawing(s) filed on is/are: a) and a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examination is objected to by the Examination The specification The specification of the specification	cepted or b) objected to by the drawing(s) be held in abeyance. Some ction is required if the drawing(s) is	See 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of: 1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the pri application from the International Bure * See the attached detailed Office action for a list	nts have been received. nts have been received in Applic ority documents have been rece au (PCT Rule 17.2(a)).	ation No ived in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/06) Paper No(s)/Mail Date	4) Interview Summ Paper No(s)/Mai 8) 5) Notice of Inform 6) Other:					

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 12/5/05 has been entered.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 3. Claims 44-47, 54-56, 60, 61, 64-68, 76, 77, 87-94 are rejected under 35 U.S.C. 102(b) as being anticipated by US 5,843,089 to Sahatjian et al. and evidenced by US 5,514,379 to Wiessleder et al.

Sahatjian teaches a stent having fenestrations (an interwoven stent); wherein the stent has a cylindrical body that is expandable between a first diameter (Fig. 1) and a second diameter (Fig. 3); and a reactive material comprising hydrogel, which is an expandable polymer (col. 1, line 66 – col. 2, line 9). Sahatjian also discloses that the hydrogel may be cross-linked *in situ* (col. 2, line 14-19). Since Sahatjian teaches the use of a hydrogel, it would be inherent that the hydrogel would have a first state of

Application/Control Number: 09/909,715

Art Unit: 3731

protonation prior to implantation and have a second state of protonation after implantation. As evidenced by Wiessleder, hydrogels that are crosslinked absorb large amounts of water (col. 3, line 36-39). Since Sahatjian teaches a fenestrated stent lined with a hydrogel, it would be inherent that the fenestration openings will decrease in size once the hydrogels have absorb water and swell up. Wiessleder also provides evidence that hydrogels react to different pHs (listed under the Examples cited in the reference). Furthermore, since Sahatjian discloses a hydrogel composition, it would inherently contain all of the characteristics cited in the claims. Also, the stent of Sahatjian is fully capable of being delivered in various methods and the diameter of the expanded stent can be substantially equal to a blood vessel (intended use/functional language). Also, Sahatjian teaches an interwoven stent, which means it could expand radially and axially; and wherein the stent is formed from stainless steel (col. 1, line 36), which is both radio-opaque and echogenic. It should also be noted that the hydrogel can be selectively applied to just portions of the stent.

Allowable Subject Matter

4. Claims 69, 81-85 and 95-100 are allowed.

Response to Arguments

5. Applicant's arguments with respect to claims 44-47, 54-56, 60, 61, 64-68, 76, 77, 87-94 have been considered but are moot in view of the new ground(s) of rejection.

Page 3

Art Unit: 3731

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Darwin P. Erezo whose telephone number is (571) 272-4695. The examiner can normally be reached on M-F (7:30-4:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anhtuan T. Nguyen can be reached on (571) 272-4963. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

de

GLENN K. DAWSON BRIMARY EXAMINER